Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Hold" from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned an average recommendation of "Hold" from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $7.30.

A number of research analysts have weighed in on the stock. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, December 12th. StockNews.com lowered Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday. They set a "neutral" rating and a $4.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently made changes to their positions in ESPR. BOKF NA acquired a new position in Esperion Therapeutics in the 2nd quarter valued at $26,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics in the third quarter worth about $27,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics in the second quarter worth about $28,000. National Bank of Canada FI boosted its position in Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at about $44,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock traded down $0.30 during trading on Wednesday, hitting $2.16. 5,826,630 shares of the company's stock were exchanged, compared to its average volume of 6,389,915. The stock has a market capitalization of $425.60 million, a price-to-earnings ratio of -3.38 and a beta of 1.01. The business has a 50-day simple moving average of $2.40 and a 200-day simple moving average of $2.22. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.